Suzhou Ark Biopharmaceutical Co., Ltd.

Haiqing Yuan

Gang Zou

Yang Zhou

Zhen Jim Wu

Cheng Peng

Shaoyun Zhang

Danbin Li

Xiashi Lv

Zhaoxiong Cai

Xiaogang Lai

Yanfei Wang

Qing Xu

Teng Feng

Rui Cui

Jian Han

Chaojun Gong

Mengfei Qian

The present disclosure provides an elastase inhibitor prodrug and use thereof, being a compound of formula I or a pharmaceutically acceptable salt, ester, isomer or solvate thereof, prodrugs or isotopically labeled compound. Compared with the compound 52 (control example) in WO 2018/175173 A1, the compound disclosed herein has the advantages of high pulmonary exposure and long half-life. The prodrugs of the present disclosure significantly increase the concentration and residence time of the active compound (control example) in the lungs with significant improvements in pharmacokinetics in vivo compared to the control example.

Elastase inhibitor prodrug and use thereof

Compositions containing the compound of general formula I: are disclosed. The compositions be used to prevent or treat hepatitis B virus infection.

Dihydroisoquinoline compound

A compound of general formula I: is disclosed. The compound be used to prevent or treat hepatitis B virus infection.

Growing community of inventors

Suzhou, China

Haiqing Yuan